Health News

Merck KGaA announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS). The application also has been granted a Priority Review designation by the FDA, which means the review period for the NDA is reduced…

Read more

Filed under: Pharmacy News
Tags: Drug, Pharmacy, sclerosis

Related posts

• XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis (0)
  XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients. Read more [tags] Pharmacy News [/tags]
  
  
• US FDA Approves Extavia(R) - The First In A New Portfolio Of Planned MS Therapies From Novartis To Help Patients With This Devastating Disease (0)
  The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease. Extavia is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of [...]
  
  
• Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA (0)
  Teva Pharmaceutical Industries Ltd. announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for a lower-volume (0.5mL) injection of glatiramer acetate. Copaxone® containing 20mg of glatiramer acetate in 1ml is the global market leader in the treatment of relapsing-remitting [...]
  
  
• Teriflunomide drug reduces relapse rate of people with MS (0)
  A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease. Read more [tags] Pharmacy News [/tags]
  
  
• Teaching an Old Drug New Tricks (0)
  A century-old drug that failed in its original intent to treat tuberculosis but has worked well as an antileprosy medicine now holds new promise as a potential therapy for multiple sclerosis and other autoimmune diseases. Read more [tags] Pharmacy News [/tags]